Crizotinib
| Price | $1000 |
| Package | 25KG |
| Min. Order: | 1KG |
| Supply Ability: | 1000KG |
| Update Time: | 2019-07-06 |
Product Details
| Product Name: Crizotinib | CAS No.: 877399-52-5 |
| EC-No.: 1308068-626-2 | Min. Order: 1KG |
| Purity: 98 | Supply Ability: 1000KG |
| Release date: 2019/07/06 |
CR077
| Crizotinib Basic information |
| Biological Activity Mechanism of action side effects |
| Product Name: | Crizotinib |
| Synonyms: | (R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylaMine;[3-[[(R)-1-(2,6-Dichloro-3- fluorophenyl)ethyl]oxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-yl]aMine;2-PyridinaMine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-;Crozotinib;Crizotinib (PF2341066);PF-02341066 Crizotinib;3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine;k-ras(g12c) inhibitor 6 NA Crizotinib |
| CAS: | 877399-52-5 |
| MF: | C21H22Cl2FN5O |
| MW: | 450.343 |
| EINECS: | 1308068-626-2 |
| Product Categories: | Inhibitor;Anti-cancer & immunity;Aromatic;Chiral Reagents;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pfizer Compounds;Pharmaceuticals |
| Mol File: | 877399-52-5.mol |
 |
|
| Crizotinib Chemical Properties |
| Safety Information |
| Safety Statements | 24/25 |
| HazardClass | IRRITANT |
| HS Code | 29333990 |
| MSDS Information |
| Crizotinib Usage And Synthesis |
| Biological Activity | Potent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable. |
| Mechanism of action | Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d’Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in the activation and dysregulation of the gene's expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrates concentration-dependent inhibition of ALK and c-Met phosphorylation in cell-based assays using tumor cell lines, and also demonstrates antitumor activity in mice bearing tumor xenografts that express EML4-or NPM-ALK fusion proteins or c-Met.Crizotinib is a multitargeted small molecule tyrosine kinase inhibitor, which had been originally developed as an inhibitor of the mesenchymal epithelial transition growth factor (c-MET); it is also a potent inhibitor of ALK phosphorylation and signal transduction. This inhibition is associated with G1-S phase cell cycle arrest and induction of apoptosis in positive cells in vitro and in vivo. Crizotinib also inhibits the related ROS1 receptor tyrosine kinase. References https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876666/ |
| side effects | crizotinib (Xalkori) is an oral receptor tyrosine kinase inhibitor indicated for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). Common side effects with Xalkori use include upper respiratory infection, nausea, vomiting, stomach pain, decreased appetite, insomnia, dizziness, tired feeling, diarrhea, constipation, rash or itching, cold symptoms (stuffy nose, sneezing, sore throat), numbness or tingling, or swelling in your hands or feet. http://www.rxlist.com/xalkori-side-effects-drug-center.htm |
| Chemical Properties | White Solid |
| Uses | A potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). A potential antitumor agent. |
| Uses | Crizotinib is a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Crizotinib is a potential antitumor agent. |
| Uses | PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley |
| Definition | ChEBI: A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients wi h locally advanced or metastatic non-small cell lung cancer (NSCLC) |
| Crizotinib Preparation Products And Raw materials |
Company Profile Introduction
Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals.
Mainly deals in the sales of:
Pharmaceutical intermediates
OLED intermediates：
Pharmaceutical intermediates;
OLED intermediates;
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-05 | ||
|
VIP2Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2026-06-02 | ||
| $44.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-26 | |
|
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-05-20 | ||
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
|
VIP7Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2025-12-15 | ||
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 | |
| $5.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2025-09-25 | |
|
Cangzhou Kangrui Pharma Tech Co. Ltd.,
|
2025-09-22 | |||
|
VIP4Y
|
Dingwang Technology (Wuhan) Co., Ltd.
|
2025-08-22 |
China- Since: 2014-12-17
- Address: Zhengzhou High tech Zone, Henan Province, China
INQUIRY
楊俊青
sales@coreychem.com
sales@coreychem.com